Surge Therapeutics Raises $32M Series B Financing To Advance Intraoperative Immunotherapy To Improve Cancer Patient Survival Outcomes Post-Surgery
Surge Therapeutics Raises $32M Series B Financing To Advance Intraoperative Immunotherapy To Improve Cancer Patient Survival Outcomes Post-Surgery
07/19/23, 12:03 PM
Location
cambridgeMoney raised
$32 million
Industry
biotechnology
health care
therapeutics
Round Type
series b
Investors
Pitango Health Tech, Khosla Ventures, Intuitive Ventures, Cancer Research Institute, Camford Capital, Alumni Ventures, 8 Vc, Piedmont Capital, Kd T Ventures, Bioluminescence Ventures
SURGE Therapeutics (SURGE), a biotech company pioneering the delivery of immunotherapy during cancer surgery, announced today the completion of a $32 million Series B financing led by Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and existing investors 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute, Intuitive Ventures, Khosla Ventures, and Pitango HealthTech.
Company Info
Location
cambridge, maryland, united states
Additional Info
SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time.
Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.